Get Started
To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.
Get in TouchThe physiological, cellular, and/or genetic basis of a disease is studied to identify potential therapeutic targets.
Once a potential target has been identified, researchers will then screen thousands of APIs, excipients and/or formulations for potential candidates that act on this target.
After early testing, however, only a small number of compounds look promising and call for further study.
We are in the age of cell therapy and gene therapy with bioprocessing being a key element. Being able to affect disease at the molecular level is the key, and nanomedicine is a fundamental technology for ushering in the next wave of genetic and molecularly targeted therapeutics.
The NanoAssemblr® Product Suite and Formulation Solutions
The NanoAssemblr® Spark™ produces microlitre volumes of nanomedicines for discovery research.
The NanoAssemblr® Ignite manufactures 1 – 15 mL of nanomedicine per run for nanomedicine development programs.
To rapidly reach the formulation proof of concept stage PNI offers highly qualified scientist with extensive formulation development experience through our Formulation Solutions Team.
At every step, our multidisciplinary experts will partner with you to build affirm scientific foundation for the work ahead.
To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.
Get in TouchPoster
September 01, 2022
Application Note
March 15, 2022
Publication - Abstract
July 01, 2020
Journal of Controlled Release
Publication - Abstract
May 08, 2020
Vaccines
Publication - Abstract
April 02, 2020
Journal of Controlled Release